非创伤性大出血的最佳纤维蛋白原阈值:一项多中心回顾性观察研究
该多中心回顾性队列研究纳入中国12个中心2018–2025年成人ICU非创伤性大出血合并低纤维蛋白原血症(纤维蛋白原<2.0 g/L)患者358例,主要预测指标为出血起病3天内治疗达到的最大纤维蛋白原水平(FIBmax)。住院死亡74例(20.7%)。校正混杂因素后FIBmax与住院死亡独立相关(每升高1 g/L,OR 0.37;95%CI 0.25–0.57;P<0.001)。限制性立方样条显示非线性剂量反应关系(非线性P=0.026),拐点2.03 g/L;FIBmax 1.5–2.0 g/L组住院死亡较2.0–2.5 g/L组高3.23倍(P=0.004),为唯一显著相邻组间转变点;>2.5 g/L无额外获益。FIBmax≥2.0 g/L者住院死亡10.1%,低于<2.0 g/L者的48.0%(P<0.001)。
要点
- 非创伤性大出血危重患者FIBmax每升高1 g/L,住院死亡OR 0.37(95%CI 0.25–0.57;P<0.001)。
- FIBmax 1.5–2.0 g/L组住院死亡较2.0–2.5 g/L组高3.23倍(P=0.004),为唯一显著相邻组间转变点。
- FIBmax≥2.0 g/L者住院死亡10.1%,<2.0 g/L者48.0%(P<0.001)。
- 限制性立方样条拐点2.03 g/L,>2.5 g/L住院死亡进入平台期、无额外获益。
- 加入FIBmax后模型区分度(AUC 0.899 vs 0.868;P=0.017)、校准(Hosmer-Lemeshow P=0.096 vs 0.031)与重分类(NRI 0.814;IDI 0.076)均改善。
适用人群与场景
- 成人ICU患者,非创伤性大出血合并低纤维蛋白原血症(纤维蛋白原<2.0 g/L),来自中国12个中心,2018–2025年。
诊断标准与关键阈值
- 低纤维蛋白原血症定义为纤维蛋白原<2.0 g/L。
- 主要预测指标为出血起病3天内治疗达到的最大纤维蛋白原水平(FIBmax)。
- 限制性立方样条拐点为2.03 g/L;相邻组间唯一显著住院死亡转变点为2.0 g/L。
研究设计与关键结果
- 多中心回顾性队列研究,纳入358例成人ICU非创伤性大出血合并低纤维蛋白原血症患者,中位年龄59岁,男性62.6%,住院死亡74例(20.7%)。
- 校正混杂因素后FIBmax与住院死亡独立相关(每升高1 g/L,OR 0.37;95%CI 0.25–0.57;P<0.001)。
- 加入FIBmax后模型区分度改善(AUC 0.899 vs 0.868;P=0.017),校准改善(Hosmer-Lemeshow P=0.096 vs 0.031),重分类改善(NRI 0.814;IDI 0.076)。
- 限制性立方样条显示非线性剂量反应关系(非线性P=0.026),拐点2.03 g/L。
- FIBmax 1.5–2.0 g/L组住院死亡较2.0–2.5 g/L组高3.23倍(P=0.004),为所有相邻组间比较中唯一显著转变点;更高水平住院死亡进入平台期,>2.5 g/L无额外获益。
- FIBmax≥2.0 g/L者住院死亡10.1%,<2.0 g/L者48.0%(P<0.001)。
证据类型、等级与局限
- 证据类型:多中心回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,非创伤性大出血危重患者治疗后纤维蛋白原水平2.0–2.5 g/L似乎最佳,2.0 g/L可能是潜在治疗阈值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current guidelines make no recommendation regarding appropriate fibrinogen replacement thresholds for non-traumatic massive bleeding. We aimed to determine the optimal post-treatment fibrinogen level associated with survival in critically ill patients with non-traumatic massive bleeding. METHODS: This multicenter retrospective cohort study enrolled adult ICU patients with non-traumatic massive bleeding and hypofibrinogenemia (fibrinogen <2.0 g/L) from 12 centers in China (2018–2025). Maximum fibrinogen level (FIBmax) achieved during treatment within 3 Days of hemorrhage onset was the primary predictor. We used the Boruta algorithm for variable selection, multivariable logistic regression to assess the independent association between FIBmax and hospital mortality, restricted cubic splines to examine dose-response relationships, and pairwise group comparisons with Bonferroni correction to identify the optimal threshold. RESULTS: Among 358 patients (median age 59 years; 62.6% male), 74 (20.7%) died during hospitalization. FIBmax was independently associated with hospital mortality after adjustment for confounders (OR 0.37 per g/L increase; 95% CI 0.25–0.57; P < 0.001). Adding FIBmax to the base model significantly improved discrimination (AUC 0.899 vs. 0.868; P = 0.017), calibration (Hosmer-Lemeshow P = 0.096 vs. 0.031), and reclassification (NRI 0.814; IDI 0.076). Restricted cubic spline analysis revealed a non-linear dose-response relationship (P for non-linearity = 0.026), with an inflection point at 2.03 g/L. Pairwise comparisons identified a significant hospital mortality transition at 2.0 g/L: patients with FIBmax of 1.5–2.0 g/L had 3.23-fold higher hospital mortality compared to those achieving 2.0–2.5 g/L (P = 0.004), representing the only significant transition point across all adjacent group comparisons. Hospital mortality plateaued at higher levels, with no additional benefit observed above 2.5 g/L. Patients achieving FIBmax ≥ 2.0 g/L had hospital mortality of 10.1% versus 48.0% for those below this threshold (P < 0.001). CONCLUSIONS: In critically ill patients with non-traumatic massive bleeding, a post-treatment fibrinogen level of 2.0–2.5 g/L appears optimal, and 2.0 g/L may represent a potential therapeutic threshold.
参考来源
- Chen S, Liu S, Ren B, et al. Optimal fibrinogen threshold in non-traumatic massive bleeding: a multicenter retrospective observational study. Crit Care. 2026. PMID: 41928278. doi:10.1186/s13054-026-05991-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。